報價延遲最少15分鐘:2026/06/10 19:21 EDT
盤後時段
|
||||
|
1.48 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.48
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.09/-0.67
|
|
企業價值
455.39M
|
| 資產負債 |
|
每股賬面淨值
0.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
75.39M
|
|
每股收益
0.02
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms. |
